Barrow Hanley Mewhinney & Strauss LLC Sells 203,325 Shares of Humana Inc. (NYSE:HUM)

Barrow Hanley Mewhinney & Strauss LLC cut its holdings in shares of Humana Inc. (NYSE:HUM) by 23.0% during the second quarter, Holdings Channel.com reports. The firm owned 680,733 shares of the insurance provider’s stock after selling 203,325 shares during the period. Barrow Hanley Mewhinney & Strauss LLC’s holdings in Humana were worth $254,356,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. raised its position in shares of Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Hantz Financial Services Inc. bought a new position in Humana in the second quarter worth about $35,000. Family Firm Inc. purchased a new stake in shares of Humana during the second quarter valued at about $37,000. Hollencrest Capital Management bought a new stake in shares of Humana in the 2nd quarter valued at about $40,000. Finally, Riverview Trust Co purchased a new position in shares of Humana in the 2nd quarter worth approximately $44,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 0.5 %

NYSE HUM opened at $310.41 on Friday. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The company has a market capitalization of $37.40 billion, a PE ratio of 19.33, a P/E/G ratio of 2.56 and a beta of 0.50. The company has a fifty day moving average of $357.71 and a 200 day moving average of $345.61.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.94 EPS. Research analysts forecast that Humana Inc. will post 16 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s payout ratio is 22.04%.

Analyst Ratings Changes

HUM has been the subject of a number of analyst reports. Royal Bank of Canada increased their target price on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. TD Cowen increased their price objective on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Baird R W raised Humana to a “hold” rating in a research report on Thursday, May 30th. Deutsche Bank Aktiengesellschaft upped their target price on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Finally, Morgan Stanley started coverage on Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target for the company. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $398.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.